Vanguard Group
TMDX icon

Vanguard Group’s Transmedics TMDX Stock Holding History

Vanguard Group’s Portfolio TMDX Stock Details TMDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		$439M Sell
3,605,279
-328
-0% -$41.2K 0.01% 1137
2025
Q3 		$405M Buy
3,605,607
+9,650
+0.3% +$1.13M 0.01% 1178
2025
Q2 		$482M Buy
3,595,957
+20,961
+0.6% +$2.3M 0.01% 1048
2025
Q1 		$241M Sell
3,574,996
-60,923
-2% -$4.19M ﹤0.01% 1396
2024
Q4 		$227M Buy
3,635,919
+40,860
+1% +$3.8M ﹤0.01% 1489
2024
Q3 		$564M Buy
3,595,059
+1,068,659
+42% +$165M 0.01% 965
2024
Q2 		$381M Buy
2,526,400
+637,306
+34% +$76.4M 0.01% 1125
2024
Q1 		$140M Buy
1,889,094
+23,979
+1% +$1.98M ﹤0.01% 1695
2023
Q4 		$147M Buy
1,865,115
+50,673
+3% +$3.06M ﹤0.01% 1670
2023
Q3 		$99.3M Buy
1,814,442
+29,798
+2% +$2.14M ﹤0.01% 1814
2023
Q2 		$150M Buy
1,784,644
+66,388
+4% +$5.08M ﹤0.01% 1626
2023
Q1 		$130M Buy
1,718,256
+26,831
+2% +$1.86M ﹤0.01% 1687
2022
Q4 		$104M Buy
1,691,425
+46,734
+3% +$2.48M ﹤0.01% 1785
2022
Q3 		$68.7M Buy
1,644,691
+208,377
+15% +$9.06M ﹤0.01% 2017
2022
Q2 		$45.2M Buy
1,436,314
+109,408
+8% +$2.92M ﹤0.01% 2244
2022
Q1 		$35.7M Sell
1,326,906
-3,613
-0.3% -$64.7K ﹤0.01% 2470
2021
Q4 		$25.5M Buy
1,330,519
+68,288
+5% +$1.71M ﹤0.01% 2711
2021
Q3 		$41.8M Buy
1,262,231
+33,453
+3% +$1.02M ﹤0.01% 2457
2021
Q2 		$40.8M Buy
1,228,778
+15,783
+1% +$437K ﹤0.01% 2478
2021
Q1 		$50.3M Buy
1,212,995
+54,528
+5% +$1.68M ﹤0.01% 2315
2020
Q4 		$23.1M Buy
1,158,467
+31,540
+3% +$467K ﹤0.01% 2562
2020
Q3 		$15.5M Buy
1,126,927
+260,899
+30% +$4.47M ﹤0.01% 2573
2020
Q2 		$15.5M Buy
866,028
+193,645
+29% +$3.03M ﹤0.01% 2548
2020
Q1 		$8.12M Buy
672,383
+18,103
+3% +$303K ﹤0.01% 2708
2019
Q4 		$12.4M Buy
654,280
+301,818
+86% +$5.54M ﹤0.01% 2751
2019
Q3 		$8.37M Buy
352,462
+43,503
+14% +$1.04M ﹤0.01% 2909
2019
Q2 		$8.96M Buy
+308,959
New +$8.43M ﹤0.01% 2919

Other funds holding TMDX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
UBS AM
UBS AM Chicago, Illinois $550B AUM 43.33% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
NAMI
Nomura Asset Management International Philadelphia, Pennsylvania $66.6B AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
HRCM
Hood River Capital Management Palm Beach Gardens, Florida $13.8B AUM 163.97% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Vanguard Group's TMDX Position: Q4 2025 in Review

Vanguard Group reduced its Transmedics (TMDX) stake by 0.01% in Q4 2025, selling an estimated $41.2K and leaving 3,605,279 shares worth $439M. The position accounts for 0.01% of the portfolio, ranked #1137.

Vanguard Group first reported a position in TMDX in Q2 2019 and has held it in 27 quarters since. The position peaked at $564M in Q3 2024. 429 funds tracked by Wall St. Rank hold TMDX as of Q4 2025.

  • Vanguard Group held 3,605,279 shares of Transmedics worth $439M as of Q4 2025.
  • Vanguard Group sold 328 Transmedics shares in Q4 2025, an estimated $41.2K.
  • Transmedics made up 0.01% of Vanguard Group's portfolio in Q4 2025, its #1137 holding.
  • Vanguard Group first reported a position in Transmedics in Q2 2019 and has held it in 27 quarters since.
  • Vanguard Group's Transmedics position peaked at $564M in Q3 2024.
  • 429 funds tracked by Wall St. Rank held Transmedics as of Q4 2025.

Based on Vanguard Group's 13F filing for Q4 2025, filed 29 Jan 2026.